首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response
【24h】

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

机译:功能扩散图:用于临床脑肿瘤反应早期分层的非侵入性MRI生物标记物

获取原文
获取原文并翻译 | 示例
       

摘要

Assessment of radiation and chemotherapy efficacy for brain cancer patients is traditionally accomplished by measuring changes in tumor size several months after therapy has been administered. The ability to use noninvasive imaging during the early stages of fractionated therapy to determine whether a particular treatment will be effective would provide an opportunity to optimize individual patient management and avoid unnecessary systemic tox-icity, expense, and treatment delays. We investigated whether changes in the Brownian motion of water within tumor tissue as quantified by using diffusion MRI could be used as a biomarker for early prediction of treatment response in brain cancer patients. Twenty brain tumor patients were examined by standard and diffusion MRI before initiation of treatment. Additional images were acquired 3 weeks after initiation of chemo- and/or radiotherapy. Images were coregistered to pretreatment scans, and changes in tumor water diffusion values were calculated and displayed as a functional diffusion map (fDM) for correlation with clinical response. Of the 20 patients imaged during the course of therapy, 6 were classified as having a partial response, 6 as stable disease, and 8 as progressive disease. The fDMs were found to predict patient response at 3 weeks from the start of treatment, revealing that early changes in tumor diffusion values could be used as a prognostic indicator of subsequent volumetric tumor response. Overall, fDM analysis provided an early biomarker for predicting treatment response in brain tumor patients.
机译:传统上,对脑癌患者的放疗和化疗疗效评估是通过在治疗数月后测量肿瘤大小的变化来完成的。在分级治疗的早期阶段使用非侵入性成像来确定特定治疗是否有效的能力将为优化个体患者管理并避免不必要的全身毒性,费用和治疗延迟提供机会。我们调查了肿瘤组织内水的布朗运动的变化(通过使用扩散MRI量化)是否可以用作早期预测脑癌患者治疗反应的生物标志物。在开始治疗之前,通过标准和扩散MRI检查了20名脑肿瘤患者。在开始化学和/或放射治疗后3周获取其他图像。将图像共同配准到预处理扫描,并计算肿瘤水扩散值的变化并显示为功能扩散图(fDM),以与临床反应相关。在治疗过程中成像的20名患者中,有6名被分类为具有部分缓解,6名为稳定疾病,8名为进行性疾病。发现fDMs可预测从治疗开始3周后的患者反应,这表明肿瘤扩散值的早期变化可以用作随后的体积肿瘤反应的预后指标。总体而言,fDM分析为预测脑肿瘤患者的治疗反应提供了早期的生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号